Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials

It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]

Renato Mantegazza, EAN 2021: Phase 3 ADAPT Study Results

touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy), to discuss the phase 3 ADAPT study results investigating efgartigimod for the treatment of myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was […]

Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine

We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at […]

Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials

It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]

The Italian Chapter of the MOST Project: Specific Changes in the Organization of Headache Centres Can Help Improve the Patient Journey

touchREVIEWS in Neurology. 2021;17(1):48-52

In 2018, the Global Burden of Disease study placed headache disorders as the second leading cause of years lived with disability.1 As another indicator of its burden, headache was ranked among the leading causes of years lived with disability.1 Given its prevalence and severe symptom burden, headache has a consequential negative impact on the quality of life […]

Opicapone: From Preclinical Data to Real-world Evidence

touchREVIEWS in Neurology. 2021;17(1):32-5

Parkinson’s disease is now considered to be a spreading disease caused by the aggregation of abnormal alpha-synuclein.1 According to Braak et al., in stage I of the disease, alpha-synuclein pathology is found in the olfactory bulb and the dorsal nucleus of the vagus nerve,2 as well as in the enteric nervous system (Auerbach’s and Meissner’s plexuses).3 These observations […]

Regional Techniques and Interventions for Intractable Neuropathic Pain

touchREVIEWS in Neurology. 2021;17(1):16-22

Neuropathic pain arises from injury to or disease in the somatosensory nervous system.1 Normal sensation and pain sensation are both impaired and patients may present with peculiar painful characteristics such as allodynia and hyperalgesia.2 Central neuropathic pain includes pain from spinal cord injury and demyelinating diseases of the spinal cord, such as multiple sclerosis.1 Lesions or disease of […]

Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease

touchREVIEWS in Neurology. 2021;17(1):36-47

Parkinson’s disease is a progressive synucleinopathy that causes widespread neurodegeneration.1 It is estimated to affect approximately 6.1 million people globally and 0.7–1.0 million people in the USA.2–4 The incidence of the disease is expected to continue to increase over time, and with it, the burden to healthcare systems.3,4 The cardinal motor symptoms, which reflect nigral dopaminergic degeneration, are bradykinesia, […]